Intravenous Infusions Statistics
Total Valuation
GHSE:IIL has a market cap or net worth of GHS 13.72 million. The enterprise value is 20.96 million.
Market Cap | 13.72M |
Enterprise Value | 20.96M |
Important Dates
The next estimated earnings date is Wednesday, December 10, 2025.
Earnings Date | Dec 10, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
GHSE:IIL has 274.41 million shares outstanding. The number of shares has decreased by -2.87% in one year.
Current Share Class | 274.41M |
Shares Outstanding | 274.41M |
Shares Change (YoY) | -2.87% |
Shares Change (QoQ) | -3.69% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | n/a |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 0.71 |
PB Ratio | 0.86 |
P/TBV Ratio | 0.86 |
P/FCF Ratio | 3.08 |
P/OCF Ratio | 2.16 |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -17.87 |
EV / Sales | 1.08 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | 4.70 |
Financial Position
The company has a current ratio of 0.84, with a Debt / Equity ratio of 0.52.
Current Ratio | 0.84 |
Quick Ratio | 0.60 |
Debt / Equity | 0.52 |
Debt / EBITDA | n/a |
Debt / FCF | 1.86 |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -6.96% and return on invested capital (ROIC) is -5.37%.
Return on Equity (ROE) | -6.96% |
Return on Assets (ROA) | -3.18% |
Return on Invested Capital (ROIC) | -5.37% |
Return on Capital Employed (ROCE) | -10.97% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | 0.43 |
Inventory Turnover | 2.10 |
Taxes
In the past 12 months, GHSE:IIL has paid 41,464 in taxes.
Income Tax | 41,464 |
Effective Tax Rate | n/a |
Stock Price Statistics
Beta (5Y) | 0.17 |
52-Week Price Change | n/a |
50-Day Moving Average | 0.05 |
200-Day Moving Average | 0.06 |
Relative Strength Index (RSI) | 54.61 |
Average Volume (20 Days) | 18,757 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GHSE:IIL had revenue of GHS 19.40 million and -1.17 million in losses. Loss per share was -0.00.
Revenue | 19.40M |
Gross Profit | 6.80M |
Operating Income | -2.28M |
Pretax Income | -1.13M |
Net Income | -1.17M |
EBITDA | -1.72M |
EBIT | -2.28M |
Loss Per Share | -0.00 |
Balance Sheet
The company has 1.06 million in cash and 8.30 million in debt, giving a net cash position of -7.24 million or -0.03 per share.
Cash & Cash Equivalents | 1.06M |
Total Debt | 8.30M |
Net Cash | -7.24M |
Net Cash Per Share | -0.03 |
Equity (Book Value) | 15.88M |
Book Value Per Share | 0.06 |
Working Capital | -3.48M |
Cash Flow
In the last 12 months, operating cash flow was 6.36 million and capital expenditures -1.90 million, giving a free cash flow of 4.46 million.
Operating Cash Flow | 6.36M |
Capital Expenditures | -1.90M |
Free Cash Flow | 4.46M |
FCF Per Share | 0.02 |
Margins
Gross margin is 35.04%, with operating and profit margins of -11.76% and -6.05%.
Gross Margin | 35.04% |
Operating Margin | -11.76% |
Pretax Margin | -5.83% |
Profit Margin | -6.05% |
EBITDA Margin | -8.86% |
EBIT Margin | -11.76% |
FCF Margin | 22.98% |
Dividends & Yields
GHSE:IIL does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | 2.87% |
Shareholder Yield | n/a |
Earnings Yield | -8.55% |
FCF Yield | 32.48% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 3 |